UNASSIGNED: Mature individuals suffering from presbyopia with Add requirements of +2.00 D or more were recruited. Monocular and binocular visual acuities were obtained across optical vergences ranging from -4.00 D to +2.00 D to generate defocus curves for best spectacle-corrected distance vision (baseline) and center-distance, catenary curve-based contact lenses (catenary). A subjective questionnaire evaluating the lenses was employed.
UNASSIGNED: Twenty-four mature individuals suffering from presbyopia, average age 59.2 (range: 51-68 years) and average Add requirement of +2.24 D (range +2.00 D to +2.50 D) were enrolled. Under high-contrast conditions, the catenary lens provided functional binocular vision (0.30 logMAR or better) at all optical vergences from distance to -3.50 D (equivalent to 28 cm). Participants demonstrated a significant improvement (p < 0.05) in binocular visual acuity while wearing the catenary lens with an imposed defocus of -1.50 D to -4.00 D (equivalent to object distances from 66 cm to 25 cm). Subjective ratings with the catenary lens were equivalent to those documented at baseline.
UNASSIGNED: The catenary curve-based lenses provided a full range of functional vision while maintaining clear distance vision for individuals suffering from advanced presbyopia. Comparison with previous results involving this lens indicates that these findings are also generalizable to wearers with lower Add requirements. This EDOF design provides a universal Add which is sufficient for advanced presbyopia.
UNASSIGNED: ClinicalTrials.gov. Identifier: NCT05495971.
■招募患有老花眼且添加要求为+2.00D或更高的成熟个体。在-4.00D至+2.00D的光学深度范围内获得单眼和双眼视力,以生成最佳的眼镜矫正远距(基线)和中心距的散焦曲线,基于悬链线曲线的隐形眼镜(悬链线)。采用评估镜片的主观问卷。
■二十四个患有老花眼的成熟个体,纳入的平均年龄为59.2岁(范围:51~68岁),平均Add要求为+2.24D(范围+2.00D~+2.50D).在高对比度条件下,悬链线透镜在距离-3.50D(相当于28厘米)的所有光学垂直度下都提供了功能性双眼视觉(0.30logMAR或更好)。参与者在佩戴悬链线透镜时表现出双目视敏度的显着改善(p<0.05),其中施加的散焦为-1.50D至-4.00D(相当于66cm至25cm的物体距离)。悬链线镜头的主观评分与基线记录的评分相同。
■基于悬链线曲线的镜片提供了全方位的功能视力,同时为患有晚期老花眼的个人保持清晰的远距视力。与涉及该镜片的先前结果的比较表明,这些发现也可推广到具有较低添加要求的佩戴者。这种EDOF设计提供了一个通用的Add,足以满足先进的老花眼。
■ClinicalTrials.gov.标识符:NCT05495971。